Maveropepimut-S clinical trials
How each study uses Maveropepimut-S is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Maveropepimut-S studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2018 | 2 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 3
ImmunoVaccine Technologies, Inc. (IMV Inc.) (4) · Providence Health & Services (1) · University Health Network, Toronto (1) · Sunnybrook Health Sciences Centre (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Maveropepimut-S is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 2ImmunoVaccine Technologies, Inc. (IMV Inc.)NCT04920617Written as DPX-Survivac
- DPX-Survivac and Checkpoint Inhibitor in DLBCLCompletedPhase 2Sunnybrook Health Sciences CentreNCT03349450Written as DPX-Survivac
- Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast CancerActive, not recruitingPhase 1Providence Health & ServicesNCT04895761Written as DPX-Survivac
- Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube CancerActive, not recruitingPhase 2University Health Network, TorontoNCT03029403Written as DPX-Survivac
- A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCLTerminatedPhase 2ImmunoVaccine Technologies, Inc. (IMV Inc.)NCT02323230Written as DPX-Survivac
- Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal CancerCompletedPhase 1ImmunoVaccine Technologies, Inc. (IMV Inc.)NCT03332576Written as DPX-Survivac
- Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal CancerCompletedPhase 1ImmunoVaccine Technologies, Inc. (IMV Inc.)NCT01416038Written as DPX-Survivac